Merck & Co Inc

NYSE:MRK   3:27:50 PM EDT
104.68
-0.86 (-0.81%)
Products

FDA Approves Keytruda As Adjuvant Treatment After Surgical Resection, Platinum-Based Chemotherapy

Published: 01/27/2023 12:08 GMT
Merck & Co Inc (MRK) - FDA Approves Keytruda® (pembrolizumab) As Adjuvant Treatment Following Surgical Resection and Platinum-based Chemotherapy for Patients With Stage Ib (t2a ≥4 Centimeters), Ii, Or Iiia Non-small Cell Lung Cancer (nsclc).
FDA Approves Keytruda® (pembrolizumab) As Adjuvant Treatment Following Surgical Resection and Platinum-based Chemotherapy for Patients With Stage Ib (t2a ≥4 Centimeters), Ii, Or Iiia Non-small Cell Lung Cancer (nsclc).
Merck & Co Inc - Two Fatal Adverse Reactions of Myocarditis Occurred in Keynote-091.